Application | Comment | Organism |
---|---|---|
medicine | by impairing prostacyclin synthase function, and thus PGI2 release, C-reactive protein, CRP, could promote endothelial dysfunction and participate in the development of coronary artery disease | Sus scrofa |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
additional information | proinflammatory C-reactive protein, CRP, selectively inhibits endothelium-dependent PGI2-induced dilation of coronary arterioles through peroxynitrite-mediated tyrosine nitration of prostacyclin synthase | Sus scrofa | |
trans-2-phenyl cyclopropylamine | - |
Sus scrofa |
Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|
52000 | - |
determined by SDS-PAGE and Western Blot analysis | Sus scrofa |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
Prostaglandin H2 | Sus scrofa | - |
Prostaglandin I2 | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Sus scrofa | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
arteriole | coronary arteriole | Sus scrofa | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
Prostaglandin H2 | - |
Sus scrofa | Prostaglandin I2 | - |
? |
Synonyms | Comment | Organism |
---|---|---|
PGI2 synthase | - |
Sus scrofa |
PGI2-S | - |
Sus scrofa |
prostacyclin synthase | - |
Sus scrofa |